DEVELOPMENT AND VALIDATION OF A REVERSE PHASE HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF CARBIDOPA AND LEVODOPA IN PHARMACEUTICAL DOSAGE FORMS

A new, simple, Accurate, precise, robust and rugged reverse phase-HPLC method was developed for the simultaneous estimation of the Levodopa and Carbidopa in pure and pharmaceutical dosage forms. Chromatogram was run through Hypersil C18 (250 mm×4.6 mm, 5μm) particle size. Mobile phase containing Potassium dihydrogen phosphate (0.03M) (pH-2.8): Methanol (75:25%) was pumped through column at a flow rate of 1.0ml/min. Temperature was maintained at Ambient. Optimized wavelength selected was 226 nm. Retention time of Levodopa and Carbidopa were found to be 1.693min and 3.235min ± 0.02 respectively. The precision %RSD of the Levodopa and Carbidopa were and found to be 0.435 and 0.039 respectively. %Recovery was obtained as 100.06% and 100.083% for Levodopa and Carbidopa respectively. Regression equation of Levodopa is y = 48138x + 5396.0., and y = 71.91x + 42.07 of Carbidopa. The LOD and LOQ values were found to be for the Levodopa and Carbidopa are 1.27µg/ml, 1.16 µg/ml 3.81µg/ml, 3.48µg/ml and the proposed method was found to be simple, precise, accurate, rapid, economic and reproducible for the estimation of Levodopa and Carbidopa in pure form and pharmaceutical marketed formulation.

Keywords: Levodopa and Carbidopa, HPLC, Method Development, Validation.